麦粒灸治疗少弱畸形精子症的临床观察

注册号:

Registration number:

ITMCTR2024000093

最近更新日期:

Date of Last Refreshed on:

2024-06-06

注册时间:

Date of Registration:

2024-06-06

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

麦粒灸治疗少弱畸形精子症的临床观察

Public title:

Clinical observation of moxibustion in the treatment of oligoasthenoteratozoospermia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于“扶阳理论”针灸治疗特发性少弱畸形精子症临床观察

Scientific title:

Clinical observation of acupuncture and moxibustion in the treatment of idiopathic oligoasthenoteratozoospermia based on the "Fuyang theory"

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

梁尚杰

研究负责人:

邱硕

Applicant:

Liang Shangjie

Study leader:

Qiu Shuo

申请注册联系人电话:

Applicant telephone:

130 7349 0549

研究负责人电话:

Study leader's telephone:

18118256591

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lsj190225@163.com

研究负责人电子邮件:

Study leader's E-mail:

jamesdatto@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市栖霞区仙林大道138号南京中医药大学

研究负责人通讯地址:

江苏省扬州市文昌中路577号

Applicant address:

Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China

Study leader's address:

No. 577, Wenchang Middle Road, Yangzhou City, Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南京中医药大学

Applicant's institution:

Nanjing University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

(2024)伦审第(22)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

扬州市中医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of Yangzhou Hospital of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2024/5/24 0:00:00

伦理委员会联系人:

张晓春

Contact Name of the ethic committee:

Zhang Xiaochun

伦理委员会联系地址:

江苏省扬州市文昌中路577号

Contact Address of the ethic committee:

No. 577, Wenchang Middle Road, Yangzhou City, Jiangsu Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

18068846073

伦理委员会联系人邮箱:

Contact email of the ethic committee:

595118716@qq.com

研究实施负责(组长)单位:

扬州市中医院

Primary sponsor:

Yangzhou Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

江苏省扬州市文昌中路577号

Primary sponsor's address:

No. 577, Wenchang Middle Road, Yangzhou City, Jiangsu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

扬州

Country:

China

Province:

Jiangsu

City:

Yangzhou

单位(医院):

扬州市中医院

具体地址:

江苏省扬州市文昌中路577号

Institution
hospital:

Yangzhou Hospital of Traditional Chinese Medicine

Address:

No. 577, Wenchang Middle Road, Yangzhou City, Jiangsu Province

经费或物资来源:

扬州市科技计划项目(YZ2023087)

Source(s) of funding:

Yangzhou Science and Technology Plan Project (YZ2023087)

研究疾病:

少弱畸形精子症

研究疾病代码:

Target disease:

oligoasthenoteratozoospermia

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

本研究旨在观察麦粒灸治疗少弱畸形精子症的疗效和安全性

Objectives of Study:

The purpose of this study was to observe the efficacy and safety of moxibustion in the treatment of oligoasthenoteratozoospermia

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)①精子浓度<15×106/ml;精子总数<39×106/ml;②精子前向运动<32%或者总活力(前向运动+非前向运动)<40%;③精子正常形态<4%;。 (2)年龄在22周岁(含)~40周岁(含)之间,男性。 (3)两周内未接受男性不育相关治疗。 (4)同意参加临床试验并签署知情同意书。

Inclusion criteria

(1)① sperm concentration < 15× 106/ml; Total sperm count < 39× 106/ml; ② PR < 32% or PR+NP < 40%; ③ Normal sperm morphology < 4%; . (2) Male between the ages of 22 (inclusive) ~ 40 years old (inclusive). (3) No male infertility related treatment within two weeks. (4) Agree to participate in clinical trials and sign informed consent.

排除标准:

(1)因生殖道先天畸形或者输精管道梗阻等泌尿系统器质性疾病引起的男性不育; (2)过敏体质,已知对本研究中药物成分过敏者; (3)具有严重的原发性心、肝、肺、肾、血液或影响其生存的严重疾病; (4)根据研究者的判断、具有降低入组可能性或使入组复杂化的其他病变,如工作环境经常变动等易造成失访的情况; (5)正在参加其他药物临床试验的患者;

Exclusion criteria:

(1) Male infertility caused by congenital malformations of the genital tract or organic diseases of the urinary system such as vas deferens obstruction; (2) Allergic constitution, known to be allergic to the drug components in this study; (3) Have serious primary heart, liver, lung, kidney, blood or serious diseases that affect their survival; (4) According to the judgment of the investigator, there are other pathologies that reduce the possibility of enrollment or complicate enrollment, such as frequent changes in the working environment, which are easy to cause loss to follow-up; (5) Patients who are participating in clinical trials of other drugs;

研究实施时间:

Study execute time:

From 2024-04-30

To      2025-03-31

征募观察对象时间:

Recruiting time:

From 2024-06-10

To      2025-03-31

干预措施:

Interventions:

组别:

左卡尼汀组

样本量:

30

Group:

L-carnitine

Sample size:

干预措施:

左卡尼汀口服液口服。左卡尼汀每次10ml,一日3次,连续服用3个月。

干预措施代码:

Intervention:

L-carnitine oral liquid is taken orally. L-carnitine 10ml each time, 3 times a day, for 3 months.

Intervention code:

组别:

麦粒灸组

样本量:

30

Group:

Moxibustion

Sample size:

干预措施:

在“关元”处施麦粒灸治疗,每次9壮。将高比例艾绒制作成5mg/壮的麦粒样艾炷,消毒后在穴位上涂抹适量凡士林固定艾炷后用线香点燃,直至燃尽。每周治疗1次,连续3个月,共计12次。

干预措施代码:

Intervention:

Moxibustion at "Guanyuan" acupoint, 9 zhuang each time. Make a high proportion of moxa wool into 5mg / strong wheat grain moxa wick. After disinfection, apply an appropriate amount of vaseline fixed moxa wick on the acupoints and light it with incense until it burns out. Treatment once a week for 12 weeks

Intervention code:

样本总量 Total sample size : 60

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

江苏

市(区县):

扬州

Country:

China

Province:

Jiangsu

City:

Yangzhou

单位(医院):

扬州市中医院

单位级别:

三甲

Institution/hospital:

Yangzhou Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

精子质量分析

指标类型:

主要指标

Outcome:

Sperm quality analysis

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

配偶怀孕率

指标类型:

次要指标

Outcome:

Pregnancy rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

安全性评估

指标类型:

次要指标

Outcome:

Safety Assessment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

精子DNA碎片指数

指标类型:

次要指标

Outcome:

DFI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清性激素水平

指标类型:

次要指标

Outcome:

Serum sex hormone levels

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

精液

组织:

Sample Name:

semen

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 22
Min age years
最大 40
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男性

Male

随机方法(请说明由何人用什么方法产生随机序列):

该部分将由一名独立的统计专家进行,使用Excel辅助完成随机分组,将60个随机数字按1∶1比例分为药物组、麦粒灸组,随机后分组信息装入不透光、密封的信封中,信封的编号和数字卡上的序号相一致,按患者进入研究的顺序,依照信封编号拆封取卡,严格按照卡片信息分组。药物组,麦粒灸组各30例。

Randomization Procedure (please state who generates the random number sequence and by what method):

This part will be carried out by an independent statistician, and the random grouping will be completed with the help of Excel. Sixty random numbers will be divided into drug group and moxibustion group according to the ratio of 1∶1. After random grouping, the information will be put into an opaque and sealed envelope, and the number of the envelope is consistent with the number on the digital card. According to the order of patients entering the study, the cards will be unpacked according to the envelope number and grouped strictly according to the card information. There were 30 cases in the drug group and 30 cases in the moxibustion group.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

与项目主持人沟通后获取

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Obtained after communicating with the project leader

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病历记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统